WallStSmart
CYTK

Cytokinetics Inc

NASDAQ: CYTK · HEALTHCARE · BIOTECHNOLOGY

$59.58
-1.83% today

Updated 2026-04-29

Market cap
$7.54B
P/E ratio
P/S ratio
85.64x
EPS (TTM)
$-6.54
Dividend yield
52W range
$29 – $71
Volume
1.9M

Cytokinetics Inc (CYTK) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
-9.3%
Last 4 quarters
Revenue YoY growth
+4.9%
Most recent quarter
EPS YoY growth
-19.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-3.2%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-7.9%
2026-02-24
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-24$-1.50+3.8%$68.26$62.89-7.9%
2025-11-05$-2.55-62.4%$59.62$60.30+1.1%
2025-08-07$-1.12+21.1%$35.14$34.11-2.9%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-1.56$-1.50+3.8%$17.75M+4.9%
2025-09-30$-1.57$-2.55-62.4%$1.94M+318.1%
2025-06-30$-1.42$-1.12+21.1%$66.77M+26714.9%
2025-03-31$-1.36$-1.36+0.2%$1.58M+89.1%
2024-12-31$-1.17$-1.26-7.3%$16.93M+912.4%
2024-09-30$-1.25$-1.36-8.8%$463000.00+22.5%
2024-06-30$-1.06$-1.31-23.6%$249000.00-71.3%
2024-03-31$-1.14$-1.33-16.7%$835000.00
2023-12-31$-0.97$-1.38-42.3%$1.67M
2023-09-30$-0.74$-1.35-82.4%$378000.00
2023-06-30$-1.15$-1.34-16.5%$867000.00

Frequently asked questions

Has Cytokinetics Inc beaten earnings estimates?
Cytokinetics Inc has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of -9.3% over the last 4 quarters.
How does CYTK stock react to earnings?
CYTK stock has moved an average of -3.2% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Cytokinetics Inc's revenue growth rate?
Cytokinetics Inc reported year-over-year revenue growth of +4.9% in its most recent quarter, with EPS growing -19.0% year-over-year.